Deborah Dunsire - Ultragenyx Independent Director
| RARE Stock | USD 42.75 0.45 1.04% |
Director
Dr. Deborah L. Dunsire, M.D., is Independent Director of the Company. Dr. Dunsire has served as a member of our Board since April 2017. Dr. Dunsire currently serves as President and Chief Executive Officer of H. Lundbeck AS, a pharmaceutical company. She previously served as President and Chief Executive Officer and as a director of Xtuit Pharmaceuticals, Inc., a private biopharmaceutical company, from January 2017 to March 2018. Prior to her position at Xtuit, she served as President and Chief Executive Officer and a director of FORUM Pharmaceuticals Inc., a private pharmaceutical company, from July 2013 to May 2016. Prior to FORUM, Dr. Dunsire worked for Takeda Pharmaceutical Company Limited, a publicly traded pharmaceutical company, as a corporate officer from June 2010 to June 2011 and a director from June 2011 to June 2013. She served as President and Chief Executive Officer and as a director of Millennium Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, between 2005 and 2008, when it was acquired by Takeda, and then as President and Chief Executive Officer of Millenium The Takeda Oncology Company after the acquisition between 2008 and 2013. Prior to Millenium, Dr. Dunsire held various roles of increasing responsibility at Novartis Pharma AG between 1988 and 2005 since 2017.
| Age | 56 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Address | 60 Leveroni Court, Novato, CA, United States, 94949 |
| Phone | 415 483 8800 |
| Web | https://www.ultragenyx.com |
Ultragenyx Management Efficiency
The company has return on total asset (ROA) of (0.2343) % which means that it has lost $0.2343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9323) %, meaning that it created substantial loss on money invested by shareholders. Ultragenyx's management efficiency ratios could be used to measure how well Ultragenyx manages its routine affairs as well as how well it operates its assets and liabilities. As of May 4, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.49. At present, Ultragenyx's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 20.3 M, whereas Other Current Assets are projected to grow to (738.3 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dennis Ausiello | Alnylam Pharmaceuticals | 72 | |
| Jakob Loven | Arvinas | 40 | |
| Andrew Saik | PDS Biotechnology Corp | 48 | |
| Jack Nielsen | Crinetics Pharmaceuticals | 54 | |
| Gary Bridger | X4 Pharmaceuticals | N/A | |
| Alec Machiels | Apellis Pharmaceuticals | 45 | |
| Raymond Kurzweil | United Therapeutics | 70 | |
| Judy Olian | United Therapeutics | 66 | |
| Christopher Causey | United Therapeutics | 55 | |
| Briggs Morrison | Arvinas | 59 | |
| Stephen Glover | PDS Biotechnology Corp | N/A | |
| Amy Schulman | Alnylam Pharmaceuticals | 57 | |
| Sarah Payne | Terns Pharmaceuticals | 41 | |
| Murray Stewart | X4 Pharmaceuticals | 57 | |
| JeanJacques Bienaime | Incyte | 64 | |
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Stephanie OBrien | Apellis Pharmaceuticals | 59 | |
| Faheem Hasnain | Kura Oncology | 59 | |
| David McGirr | X4 Pharmaceuticals | 63 | |
| Bradley Margus | Arvinas | 57 | |
| Tommy Thompson | United Therapeutics | 76 | |
Management Performance
| Return On Equity | -1.93 | ||||
| Return On Asset | -0.23 |
Ultragenyx Leadership Team
Elected by the shareholders, the Ultragenyx's board of directors comprises two types of representatives: Ultragenyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ultragenyx. The board's role is to monitor Ultragenyx's management team and ensure that shareholders' interests are well served. Ultragenyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ultragenyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Pinion, Chief Quality Operations Officer and Senior Vice President Analytical Sciences and Research | ||
| Karah Parschauer, Executive Vice President General Counsel | ||
| Shalini Sharp, CFO and Sr. VP | ||
| Daniel Welch, Director | ||
| Camille Bedrosian, Chief Medical Officer and Executive Vice President | ||
| Dennis Huang, Chief Technical Operations Officer and Sr. VP | ||
| Lars Ekman, Independent Director | ||
| Alison Skrinar, Vice Evaluation | ||
| Emil Kakkis, President CEO, Board Member | ||
| Jayson Dallas, Senior Vice President Chief Commercial Officer | ||
| Danielle Keatley, Senior Communications | ||
| Samuel Wadsworth, Chief Therapy | ||
| Ernie Meyer, Chief VP | ||
| Karah JD, Chief Affairs | ||
| John II, Chief Sciences | ||
| Deborah Dunsire, Independent Director | ||
| Michael Narachi, Director | ||
| Howard Horn, Executive CFO | ||
| Arjun Natesan, Vice Research | ||
| Vimal Srivastava, Senior Management | ||
| Sunil Agarwal, Chief Medical Officer, Senior Vice President | ||
| Aaron Olsen, Senior Finance | ||
| Paul JD, Vice Property | ||
| Theodore Huizenga, Corporate VP | ||
| Erik Harris, Executive Vice President and Chief Commercial Officer | ||
| Camille MD, Chief VP | ||
| Matthew Fust, Independent Director | ||
| Shehnaaz Suliman, Independent Director | ||
| Clay Siegall, Independent Director | ||
| Thomas Kassberg, Chief Bus. Officer and Sr. VP | ||
| Eric MD, Chief VP | ||
| William Aliski, Independent Director | ||
| Wladimir Hogenhuis, COO |
Ultragenyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ultragenyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.93 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.40) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | 3.91 B | ||||
| Shares Outstanding | 83.13 M | ||||
| Shares Owned By Insiders | 4.02 % | ||||
| Shares Owned By Institutions | 95.98 % | ||||
| Number Of Shares Shorted | 4.38 M | ||||
| Price To Earning | (6.90) X |
Ultragenyx Investors Sentiment
The influence of Ultragenyx's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Ultragenyx. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Ultragenyx's public news can be used to forecast risks associated with an investment in Ultragenyx. The trend in average sentiment can be used to explain how an investor holding Ultragenyx can time the market purely based on public headlines and social activities around Ultragenyx. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ultragenyx's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ultragenyx's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Ultragenyx's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Ultragenyx.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ultragenyx in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ultragenyx's short interest history, or implied volatility extrapolated from Ultragenyx options trading.
Currently Active Assets on Macroaxis
| LAAC | Lithium Americas Corp | |
| F | Ford Motor | |
| CHPT | ChargePoint Holdings | |
| AXL | American Axle Manufacturing | |
| ICLN | iShares Global Clean |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Ultragenyx Stock analysis
When running Ultragenyx's price analysis, check to measure Ultragenyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ultragenyx is operating at the current time. Most of Ultragenyx's value examination focuses on studying past and present price action to predict the probability of Ultragenyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ultragenyx's price. Additionally, you may evaluate how the addition of Ultragenyx to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Ultragenyx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.25) | Revenue Per Share 5.905 | Quarterly Revenue Growth 0.233 | Return On Assets (0.23) | Return On Equity (1.93) |
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.